ONCT News and Press, Oncternal Therapeutics Inc. From 08/27/20

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commi...

Oncternal Therapeutics (NASDAQ: ONCT ) inks securities purchase agreement with underwriter to offer 1.67M shares of common stock priced at $2.10 per share; underwriters' overallotment option is additional 250K shares.  More news on: Oncternal Therapeutics, Inc., Healthcare stocks ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purc...

Oncternal Therapeutics, Inc. (ONCT) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Richard Vincent – Chief Financial Officer Jim Breitmeyer – President & Chief Executive Officer Frank Hsu – Chief Medical Officer Confere...

- 58% complete response rate reported in patients with relapsed/refractory mantle cell lymphoma (MCL) in ongoing Phase 1/2 clinical trial of cirmtuzumab with ibrutinib, and the regimen was well tolerated. Meeting requested with FDA to discuss registration pathway for cirmtuzumab for patient...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020 financial results after U.S. financial markets close on Thursday, August 6, 2020. Oncternal&#...

Call on Wednesday, July 29 th @ 1:30 p.m. Eastern Time; register here Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader (K...

Gainers:  Global Eagle Entertainment ENT  +164% . More news on: Hamilton Beach Brands Holding Company, Wilhelmina International, Inc., Oncternal Therapeutics, Inc., Stocks on the move, , Read more ...

Natuzzi (NYSE: NTZ ) +131%  on renewing its securitization facility. More news on: Natuzzi S.p.A., Miragen Therapeutics, Theratechnologies Inc., Stocks on the move, Read more ...

Oncternal Therapeutics (NASDAQ: ONCT )   -8.7%  in pre-market, to offer ~2.6M shares at $2.3825/share, in a registered direct offering. More news on: Oncternal Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...